He-Jin Lee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11057879/publications.pdf

Version: 2024-02-01

50 papers	13,464 citations	87888 38 h-index	189892 50 g-index
50 all docs	50 docs citations	50 times ranked	20638 citing authors

#	Article	IF	Citations
1	Senescence and impaired DNA damage responses in alpha-synucleinopathy models. Experimental and Molecular Medicine, 2022, 54, 115-128.	7.7	25
2	Alpha-Synuclein Inclusion Formation in Human Oligodendrocytes. Biomolecules and Therapeutics, 2021, 29, 83-89.	2.4	5
3	Arylsulfatase A, a genetic modifier of Parkinsonâ€™s disease, is an Î±-synuclein chaperone. Brain, 2019, 142, 2845-2859.	7.6	44
4	Models of multiple system atrophy. Experimental and Molecular Medicine, 2019, 51, 1-10.	7.7	18
5	Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating Î±-synuclein transmission and neuroinflammation. Molecular Neurodegeneration, 2018, 13, 43.	10.8	117
6	LRRK2 kinase regulates Î±-synuclein propagation via RAB35 phosphorylation. Nature Communications, 2018, 9, 3465.	12.8	121
7	Mechanism of neuroprotection by trehalose: controversy surrounding autophagy induction. Cell Death and Disease, 2018, 9, 712.	6.3	133
8	Amplification of distinct Î±-synuclein fibril conformers through protein misfolding cyclic amplification. Experimental and Molecular Medicine, 2017, 49, e314-e314.	7.7	39
9	Is trehalose an autophagic inducer? Unraveling the roles of non-reducing disaccharides on autophagic flux and alpha-synuclein aggregation. Cell Death and Disease, 2017, 8, e3091-e3091.	6.3	50
10	Cell-to-cell Transmission of Polyglutamine Aggregates inC. elegans. Experimental Neurobiology, 2017, 26, 321-328.	1.6	19
11	Non-cell-autonomous Neurotoxicity of Î±-synuclein Through Microglial Toll-like Receptor 2. Experimental Neurobiology, 2016, 25, 113-119.	1.6	77
12	Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function. Autophagy, 2016, 12, 1849-1863.	9.1	59
13	Exposure to bacterial endotoxin generates a distinct strain of Î±-synuclein fibril. Scientific Reports, 2016, 6, 30891.	3.3	113
14	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
15	Cell Models to Study Cell-to-Cell Transmission of Î±-Synuclein. Methods in Molecular Biology, 2016, 1345, 291-298.	0.9	7
16	Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and Î±-synuclein aggregation. Experimental and Molecular Medicine, 2015, 47, e153-e153.	7.7	77
17	Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. Cell Reports, 2015, 13, 771-782.	6.4	113
18	ATP13A2/PARK9 Deficiency Neither Cause Lysosomal Impairment Nor Alter Î±-Synuclein Metabolism in SH-SY5Y Cells. Experimental Neurobiology, 2014, 23, 365-371.	1.6	8

#	Article	IF	Citations
19	Î²1-integrin-dependent migration of microglia in response to neuron-released Î±-synuclein. Experimental and Molecular Medicine, 2014, 46, e91-e91.	7.7	48
20	Extracellular Î±-synucleinâ€"a novel and crucial factor in Lewy body diseases. Nature Reviews Neurology, 2014, 10, 92-98.	10.1	255
21	Glucocerebrosidase depletion enhances cell-to-cell transmission of Î±-synuclein. Nature Communications, 2014, 5, 4755.	12.8	157
22	Neuron-released oligomeric Î±-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nature Communications, 2013, 4, 1562.	12.8	634
23	Autophagic failure promotes the exocytosis and intercellular transfer of Î±-synuclein. Experimental and Molecular Medicine, 2013, 45, e22-e22.	7.7	163
24	Glucocerebrosidase, a new player changing the old rules in Lewy body diseases. Biological Chemistry, 2013, 394, 807-818.	2.5	14
25	Lipid Peroxidation Product 4-Hydroxy-2-Nonenal Promotes Seeding-Capable Oligomer Formation and Cell-to-Cell Transfer of Î±-Synuclein. Antioxidants and Redox Signaling, 2013, 18, 770-783.	5.4	99
26	LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinsonâ€™s Disease. Experimental Neurobiology, 2013, 22, 249-257.	1.6	18
27	Valproic Acid Regulates Î±-Synuclein Expression through JNK Pathway in Rat Primary Astrocytes. Biomolecules and Therapeutics, 2013, 21, 222-228.	2.4	9
28	Antibody-Aided Clearance of Extracellular Î±-Synuclein Prevents Cell-to-Cell Aggregate Transmission. Journal of Neuroscience, 2012, 32, 13454-13469.	3.6	290
29	Cell-to-Cell Transmission of Î±-Synuclein Aggregates. Methods in Molecular Biology, 2012, 849, 347-359.	0.9	45
30	Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Experimental and Molecular Medicine, 2011, 43, 216.	7.7	117
31	Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives. Neuroscience Research, 2011, 70, 339-348.	1.9	154
32	Transmission of Synucleinopathies in the Enteric Nervous System of A53T Alpha-Synuclein Transgenic Mice. Experimental Neurobiology, 2011, 20, 181-188.	1.6	39
33	Enzyme-linked immunosorbent assays for alpha-synuclein with species and multimeric state specificities. Journal of Neuroscience Methods, 2011, 199, 249-257.	2.5	24
34	Nonâ€classical exocytosis of Î±â€synuclein is sensitive to folding states and promoted under stress conditions. Journal of Neurochemistry, 2010, 113, 1263-1274.	3.9	241
35	Alpha-Synuclein Stimulation of Astrocytes: Potential Role for Neuroinflammation and Neuroprotection. Oxidative Medicine and Cellular Longevity, 2010, 3, 283-287.	4.0	133
36	Multiple non-cell autonomous actions of Î±-synuclein in neurodegenerative diseases. Cell Cycle, 2010, 9, 2696-2697.	2.6	6

#	Article	IF	Citations
37	Direct Transfer of Î±-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies. Journal of Biological Chemistry, 2010, 285, 9262-9272.	3.4	704
38	Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha-synuclein in rat primary glial cells. Neuroscience Letters, 2010, 469, 352-356.	2.1	28
39	Inclusion formation and neuronal cell death through neuron-to-neuron transmission of Î±-synuclein. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13010-13015.	7.1	1,308
40	Assembly-dependent endocytosis and clearance of extracellular a-synuclein. International Journal of Biochemistry and Cell Biology, 2008, 40, 1835-1849.	2.8	428
41	Clearance and deposition of extracellular Î±-synuclein aggregates in microglia. Biochemical and Biophysical Research Communications, 2008, 372, 423-428.	2.1	273
42	Impairment of microtubule-dependent trafficking by overexpression of Î±-synuclein. European Journal of Neuroscience, 2006, 24, 3153-3162.	2.6	142
43	Intravesicular Localization and Exocytosis of Î±-Synuclein and its Aggregates. Journal of Neuroscience, 2005, 25, 6016-6024.	3.6	722
44	Clearance of Â-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway. Journal of Neuroscience, 2004, 24, 1888-1896.	3.6	383
45	Formation and Removal of Î±-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors. Journal of Biological Chemistry, 2002, 277, 5411-5417.	3.4	263
46	Characterization of Cytoplasmic Î±-Synuclein Aggregates. Journal of Biological Chemistry, 2002, 277, 48976-48983.	3.4	164
47	Membrane-bound Î±-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form. Journal of Biological Chemistry, 2002, 277, 671-678.	3.4	411
48	Golgi Fragmentation Occurs in the Cells with Prefibrillar Î±-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion. Journal of Biological Chemistry, 2002, 277, 48984-48992.	3.4	249
49	Stabilization of Partially Folded Conformation during Î±-Synuclein Oligomerization in Both Purified and Cytosolic Preparations. Journal of Biological Chemistry, 2001, 276, 43495-43498.	3.4	164
50	Tip60 and HDAC7 Interact with the Endothelin Receptor A and May Be Involved in Downstream Signaling. Journal of Biological Chemistry, 2001, 276, 16597-16600.	3.4	53